Amicus Stockholders Approve BioMarin Acquisition at Special Meeting
at www.tipranks.com (Tue, 3-Mar 4:34 PM)
BioMarin’s $4.8B Deal to Acquire Amicus Therapeutics (FOLD) Puts Rare Disease Innovation in the Spotlight
Market Chameleon (Fri, 19-Dec 10:30 AM)
BioMarin’s $4.8B Acquisition of Amicus: Strategic Expansion, Immediate Growth, and Shareholder Value in Rare Disease
Market Chameleon (Fri, 19-Dec 8:40 AM)
